Dr. Everett Vokes, MD

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Chicago

  Fellowship Hospital, 1986

• University Sthrn Ca Los Angeles Co Hospital

  Residency Hospital, 1983

• University Il/ravenswood Hospital

  Residency Hospital, 1982

• Med Fac Rhein, F Wilhelms University Bonn

  Medical School, 1980

• Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies, 2011-07-26

• A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602), 2010-03-20

• Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment, 2022-01-03

• The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium, 2009-08-11

• Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097), 2010-06-28

• Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B trial 9430, 2009-01-13

• Positive Interaction Between Prophylactic Cranial Irradiation And Maintenance Sunitinib For Untreated Extensive Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis Of CALGB 30504 (Alliance), 2015-12-24

• Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium, 2012-07-23

• A Phase 2 Study of Cetuximab in Combination With Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Nonsmall Cell Lung Cancer, 2009-04-15

• Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance), 2017-02-01

• ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early Stage Non-Small Cell Lung Cancer, 2015-12-15

• Combination MET inhibition and Topoisomerase I inhibition block cell growth of Small Cell Lung Cancer, 2013-12-10

• Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy, 2013-06-10

• A phase II study of halichondrin B analogue eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California Cancer Consortium trial, 2011-12-09

• Risk and Response Adapted De-Intensified Treatment for HPV-Associated Oropharyngeal Cancer: OPTIMA Paradigm Expanded Experience., 2021-10-18

• Germline Polymorphisms Discovered via a Cell-based Genome-wide Approach Predict Platinum Response in Head and Neck Cancers, 2011-02-08

• Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer, 2013-12-04

• Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology, 2022-11-02

• NovelEPHB4Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer, 2015-06-15

• Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness ofCaenorhabditis elegansmodel organism, 2011-03-03

• DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer, 2014-07-14

• Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer, 2015-07-20

• Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those ofin vitroexpanded populations in head and neck cancer, 2017-12-19

• PAX5 is expressed in small cell lung cancer and positively regulates c-Met transcription, 2009-01-12

• Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe, 2016-06-27

• A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck, 2022-12-01

• A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, 2009-02-07

• Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use, 2019-06-25

• Comparative effects of CT imaging measurement on RECIST endpoints and tumor growth kinetics modeling, 2016-01-21

• CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases, 2010-01-29

• Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database, 2011-02-28

• Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer, 2015-09-27

• Clinical prognostic model for older patients with advanced non-small cell lung cancer, 2019-02-21

• Heuristic value-based framework for lung cancer decision-making, 2018-07-06

• Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation, 2011-05-13

• MET as a target for treatment of chest tumours, 2008-07-30

• Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer, 2014-01-04

• Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation, 2016-02-26

• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression, 2018-04-17

• Expression and Mutational Analysis ofMETin Human Solid Cancers, 2008-10-31

• Bortezomib for Patients with Advanced Stage Bronchioloalveolar Carcinoma (BAC): A California Cancer Consortium Phase II Study (NCI # 7003), 2011-11-01

• MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer, 2009-11-24

• Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma, 2016-05-26

• Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma, 2022-04-13

• Protein kinase C beta (PKCß) in malignant pleural mesothelioma, 2008-10-23

• Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105, 2011-04-07

• Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC), 2015-03-26

• Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer, 2018-10-04

• Efficacy of the Multi-Kinase Inhibitor Enzastaurin is Dependent on Cellular Signaling Context, 2010-09-28

• Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer, 2009-09-01

• Randomized Study of Maintenance Pemetrexed versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901, 2020-07-03

• The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target, 2013-07-02

• A Phase II Study of Sorafenib in Advanced Uterine Carcinoma / Carcinosarcoma: A Trial of the Chicago, PMH, and California Phase II Consortia, 2010-02-01

• Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report, 2012-02-08

• "Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer”, 2009-10-09

• Adjuvant treatment for high-risk salivary gland malignancies and prognostic stratification based on a 20-year single institution experience, 2020-10-07

• Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity, 2021-02-24

• Impact of nivolumabvsstandard, single-agent therapy of investigator's choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141, a randomized, phase 3 trial, 2017-06-23

• Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer, 2014-03-14

• Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL, 2017-08-23

• Factors Associated with Clinical Benefit from Epidermal Growth Factor Receptor Inhibitors in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck, 2009-07-07

• A Phase I Trial Adding Poly(ADP-ribose) Polymerase Inhibitor Veliparib to Induction Carboplatin-Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Alliance A091101, 2021-01-26

• Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107), 2011-12-22

• Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium, 2010-08-28

• A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck, 2012-02-27

• Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited stage small cell lung cancer: CALGB 30206, 2012-11-11

• A randomized phase II network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma., 2020-02-19

• A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly compared to younger patients, 2018-10-21

• A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer, 2014-12-13

• Integrated Genomic Analysis SuggestsMLL3is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma, 2015-05-26

• Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients, 2018-04-13

• The MET Receptor Tyrosine Kinase is a potential novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma, 2009-03-24

• Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database, 2011-02-28

• Prognostic Significance of Mucin and p53 Expression in Stage IB Non-Small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633, 2010-05-06

• Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904, 2013-11-30

• Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium, 2011-05-07

• A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer, 2019-09-04

• CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer, 2021-10-08

• Phase I Study of Accelerated Hypofractionated Radiotherapy with Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer: CALGB 31102 (Alliance), 2018-01-31

• Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas, 2014-07-23

• Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits, 2022-07-31

• A Pooled Analysis of Limited Stage Small Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904, 2013-10-17